Market Resilience: Ultragenyx Pharmaceutical Inc (RARE) Finishes Weak at 46.02, Down -0.82

For those desiring to outshine the market, the strategic selection of individual stocks is paramount. Well-chosen stocks have the potential to substantially boost your wealth.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) closed the day trading at $46.02 down -0.82% from the previous closing price of $46.40. In other words, the price has decreased by -$0.82 from its previous closing price. On the day, 0.53 million shares were traded. RARE stock price reached its highest trading level at $47.14 during the session, while it also had its lowest trading level at $45.905.

Ratios:

For a better understanding of RARE, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.65 and its Current Ratio is at 2.81. In the meantime, Its Debt-to-Equity ratio is 2.63 whereas as Long-Term Debt/Eq ratio is at 2.46.

Upgrades & Downgrades

In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Goldman on June 06, 2024, Upgraded its rating to Buy and sets its target price to $67 from $56 previously.

On April 22, 2024, RBC Capital Mkts started tracking the stock assigning a Outperform rating and target price of $77.

On December 08, 2023, Wells Fargo started tracking the stock assigning a Overweight rating and target price of $72.Wells Fargo initiated its Overweight rating on December 08, 2023, with a $72 target price.

Insider Transactions:

The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Oct 10 ’24 when Horn Howard sold 7,465 shares for $52.76 per share. The transaction valued at 393,853 led to the insider holds 92,301 shares of the business.

KAKKIS EMIL D sold 20,000 shares of RARE for $1,117,000 on Sep 03 ’24. The President & CEO now owns 2,223,985 shares after completing the transaction at $55.85 per share. On Sep 03 ’24, another insider, Huizenga Theodore Alan, who serves as the SVP, Chief Accounting Officer of the company, sold 91 shares for $56.19 each. As a result, the insider received 5,113 and left with 41,551 shares of the company.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RARE now has a Market Capitalization of 4249684992 and an Enterprise Value of 4558501376. For the stock, the TTM Price-to-Sale (P/S) ratio is 8.13 while its Price-to-Book (P/B) ratio in mrq is 12.24. Its current Enterprise Value per Revenue stands at 8.72 whereas that against EBITDA is -9.098.

Stock Price History:

Over the past 52 weeks, RARE has reached a high of $60.37, while it has fallen to a 52-week low of $37.02. The 50-Day Moving Average of the stock is -13.76%, while the 200-Day Moving Average is calculated to be -4.36%.

Shares Statistics:

Over the past 3-months, RARE traded about 727.71K shares per day on average, while over the past 10 days, RARE traded about 916640 shares per day. A total of 92.34M shares are outstanding, with a floating share count of 86.32M. Insiders hold about 6.53% of the company’s shares, while institutions hold 95.03% stake in the company. Shares short for RARE as of 1730332800 were 3179627 with a Short Ratio of 4.37, compared to 1727654400 on 2887535. Therefore, it implies a Short% of Shares Outstanding of 3179627 and a Short% of Float of 3.95.

Most Popular